

ASTRAZENECA 2008 US RESPONSIBLE BUSINESS REPORT

RESPONSIBLE BUSINESS, HEALTHIER PEOPLE



Contents

A Letter from Rich Fante	3
Responsible Business, Healthier Company	4
Responsible Business, Healthier People	12
Responsible Business, Healthier Communities	19
Responsible Business, Healthier Environment	29

About the Report

This Responsible Business Report details the social, economic and environmental activities of AstraZeneca Pharmaceuticals LP. Most of this report addresses our activities in the United States, although portions summarize the AstraZeneca approach to responsible business at the global level.

Reporting Time Frame

All reported data are for the 2008 calendar year, unless otherwise noted. We update information and metrics on our responsible business Web site throughout the year.

Global Reporting Initiative

The principles set forth in both the Global Reporting Initiative (GRI) Guidelines and the AA1000 Assurance Standards were used as a guide while preparing this report.

Policy Considerations

The pharmaceutical industry in the United States is highly regulated, therefore public policy at the federal, state and local levels often influences decisions. Key issues addressed throughout this report, particularly in the Corporate Governance and Compliance, Sales and Marketing, Access to Medicines, Patient Safety and Clinical Trials sections, reflect policy priorities.

AstraZeneca regularly identifies and explores key issues and engages the public, legislators and policy makers on important health policy initiatives for the benefit of the people who use our medicines. In addition to our own advocacy efforts, we work closely with the Biotechnology Industry Organization (BIO) and our industry trade association, the Pharmaceutical Research and Manufacturers of America (PhRMA), which lobbies and communicates on behalf of the industry and its members, including AstraZeneca.

A Letter from our US President

WELCOME

On behalf of everyone at AstraZeneca US, I am pleased to present this year's Responsible Business Report.

AstraZeneca is one of the world's leading pharmaceutical companies, and at the heart of our business lies a single purpose: making a difference in people's health through meaningful medicines. Having a pipeline of such medicines is the most important contribution we can make to public health. But we also challenge ourselves by asking every day: What more can a pharmaceutical company do to improve healthcare and society at large? While we do not have all of the answers, we do know that how we act, and treat people, is as important as the medicines we make.

We frame communications on our business operations through a platform called "Responsible Business, Healthier People" that is supported by four guiding principles:

- *Ethical behavior*, which is critical to advancing patient health;
- *Focus on patients*, so that our medicines can help people stay healthy and not just treat illnesses, but also help them to live longer lives;
- *Collaboration* with public health advocacy groups, patient organizations and communities to advance health;
- *Inclusion*, to improve the healthcare needs of people across diverse backgrounds and cultures, some of which have the greatest need, but the least amount of access to health services and medicines.

AstraZeneca's success is built on the trust and confidence that our stakeholders have in our medicines, relationships, and corporate integrity. We played a leading role in the development of the PhRMA Code on Interactions with Healthcare Professionals. These guidelines ensure that interactions between pharmaceutical companies and healthcare providers are conducted ethically and responsibly.

We are also providing more information to the public about our company, our medicines and how we do business.

Beginning in 2008, AstraZeneca is biannually reporting our contributions to nonprofit organizations, along with descriptions of the sponsored program or project. These reports can be found on AstraZeneca's [US Web site](#). In 2008, we donated \$41.4 million to non-profit organizations for programs and projects designed to promote health in our country.

We are also taking a serious look at our impact on the environment. In the US, we are participating in the Environmental Protection Agency's (EPA) Energy Star program, implementing sustainable facilities design through LEED®, and investing in other energy-saving technologies such as solar panels, wind energy credits, and hybrid engine vehicles. AstraZeneca's efforts were recognized by the EPA for superior energy conservation performance.

This past November I became President of AstraZeneca Pharmaceuticals' US Business, taking over when AstraZeneca is at the beginning of a major transformation. Improving our nation's health and healthcare are among the most important challenges we face, and meeting them will not be easy. To do so and deliver on our promise of advancing life-changing medicines, AstraZeneca is changing how we operate as a company, and we cannot do it alone. We are partnering with patients, physicians, other companies, our local communities and lawmakers to improve the state of healthcare.

I am proud to work for AstraZeneca, which is up for this challenge, so we can make a difference in the health of our families, our local communities, and millions of patients worldwide.

I invite you to learn more about us and join our efforts to improve healthcare.

Yours in Health,

Rich Fante



Responsible Business, Healthier Company

The nature of AstraZeneca's business—discovering and developing meaningful medicines to save and improve lives—is to deliver a tremendous benefit to society. As one of the world's leading pharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that make a real difference in important areas of healthcare. We also believe responsible and ethical business practices are critical to advancing patient health. For us, responsible business is a continuing process of improvement that we strive to reflect every day in our decisions and actions.

AstraZeneca was recognized for our efforts to foster a healthy workforce and as an employer of choice. We again received CEO Gold Standard reaccreditation by the CEO Roundtable on Cancer and worked to reach mental health parity in our health plans, offering the same level of mental health care coverage as medical and surgical benefits. In addition to changing our own health plans, we promoted federal legislation requiring other employers to offer the same level of coverage.

2008 Ethics and Compliance Highlights:

- Established a cross-business Responsible Business Team to align AstraZeneca US responsible business strategy with the company's global strategies and practices
- Strengthened global Code of Conduct for AstraZeneca US employees
- Supported 14 employee networking groups to encourage diversity
- Received recognition as employer of choice on *FORTUNE's* 100 Best Places to Work, *Working Mother's* 100 Best Companies for Working Mothers, and the Top 20 of *Diversity MBA* Best Companies, among others
- Continued to integrate responsible business in our global purchasing category management processes



Responsible Business, Healthier Company

Our Responsible Business Approach

Compliance with clear standards and policies is essential to our company's integrity, reputation, and most important, to our mission to make medicines that help people live longer, healthier lives.

To foster greater consistency throughout our organization, **we aligned US responsible business with global and US business governance teams in 2008.** The following outlines how we structure our business to adhere to the highest ethical standards.

Global:

- The Global Corporate Responsibility Team leads the development of the AstraZeneca responsible business strategy, making sure that this strategy is aligned with business objectives
- AstraZeneca Board of Directors owns the company's global strategy
- A non-executive director oversees the implementation of the responsible business strategy
- Our Senior Executive Team (SET) and senior managers throughout the company are accountable for responsible business management within areas, taking into account national, functional and site issues and priorities



Structured for Success: The US Responsible Business Team

Launched in 2008, the Responsible Business Team (RBT) spearheads responsible business efforts for AstraZeneca US.

Composed of a cross-functional management team, the RBT recommends US responsible business strategy, creates the US Responsible Business Action Plan, and leads the plan's implementation across the US organization. The team coordinates with AstraZeneca globally to ensure that our US efforts align with corporate expectations and global priorities.

US:

- The Responsible Business Team oversees responsible business strategy in the US and makes sure US strategy is aligned with global strategies and practices
- Our Leading Externally Team (LET) drives the understanding of key external stakeholder perspectives and sponsors the Responsible Business Team
- Our Business Integrity and Assurance Team (BIAT) leads AstraZeneca US in setting standards for ethical business practices and policies
- Our Leading through Innovation Team (LTI) drives transformational change in the way AstraZeneca US delivers meaningful medicines to patients
- Our Leading Through People Team (LTP) sets and drives the adoption of the standards for establishing AstraZeneca US as an industry leader in the areas of employee engagement, diversity and developing a high-performance culture, accountable leaders and robust talent pipeline
- All of the above governance teams are accountable to the AstraZeneca US Leadership Team led by US President Rich Fante

Reporting our Performance

Our parent company, AstraZeneca PLC, publishes information on our global commitment to responsible business in our Annual Report and Form 20-F Information (www.astrazeneca.com/annualreport2008). We also have a section of our international Web site dedicated to responsible business practices (www.astrazeneca.com/responsibility).

Responsible Business, Healthier Company

Building Awareness and Commitment for Responsible Business

In 2008, AstraZeneca updated its global [Code of Conduct](#) to ensure more consistent policies and practices at our sites around the world. All of our US employees and key external resource staff, such as contractors and suppliers, received training on our Code of Conduct, as well as on other policies that pertain to their roles in sustaining our company's ethical culture. Responsible business principles and practices are also regularly integrated into a range of communications to employees to ensure that responsible behavior is part of everyone's daily working life.

This year, we added several comprehensive employee communication programs focused on compliance and ethics, including a new "Openness" program, which is designed to assure employees that if they report an alleged ethics violation, their report will get investigated and appropriate action will be taken.

AstraZeneca US Compliance Program

We maintain a comprehensive US Compliance Program to prevent, detect and correct violations of company policies and procedures, as well as violations of applicable laws, regulations and external standards.

In the past year, we have identified certain compliance violations and handled these instances in accordance with our policies. As technology and the external climate evolve, we will continue to adjust and realign our policies. For example, we developed new policies surrounding social media usage by employees and vendors to ensure consistency with AstraZeneca's ethical guidelines.

Our US Compliance Officer leads this program and manages a department dedicated to this effort. AstraZeneca has adopted US-specific policies and procedures that are aligned with our Global Code of Conduct and the new Pharmaceutical Research and Manufacturers of America (PhRMA) Code. The AstraZeneca US Compliance Program is in accordance

with the general principles of the Office of Inspector General (OIG) Compliance Program Guidance for Pharmaceutical Manufacturers that the US Department of Health and Human Services issued in 2003. An overview of our US Compliance Program is available at AstraZeneca's [US Web site](#).

To ensure that all our employees understand our commitment to compliance, we deliver mandatory compliance training for all new hires as well as job-specific compliance training for current staff. Each year, every AstraZeneca US employee and key external resource personnel must complete mandatory Code of Conduct training designed to keep employees informed of key AstraZeneca policies and policy updates.

In 2008, AstraZeneca employees and key external resource personnel completed 33,789 compliance and ethics training sessions. We also completed our two-hour "Ethics in the Workplace" workshop required of all managers, from the US Leadership Team down to first-line managers. In 2007, 1,027 managers attended these workshops, which were designed and developed by the International Business Ethics Institute specifically for AstraZeneca, and in 2008 an additional 552 field-based managers completed them.

The workshop objectives were to help managers:

- Understand how decisions, actions and behaviors affect the ethical climate of the organization
- Strengthen ethical decision-making skills; align decisions, actions and behaviors with company values and the Code of Conduct
- Learn the necessary skills and tools to manage ethics effectively and to enhance understanding of key issues from the Code of Conduct by discussing complex ethical scenarios and cases requiring ethical decisions

Also in 2008, the basics of the Ethics in the Workplace workshops were integrated into our new and incumbent manager training programs in order to sustain the concepts of an ethical work environment over time.

Responsible Business, Healthier Company

Complementing our compliance training is our rigorous auditing program, which helps ensure an independent and objective review and assessment of our compliance efforts. In addition to formal audits, we monitor specific risk areas through periodic compliance assessments. In November 2008, Bureau Veritas, an independent assurance group, visited AstraZeneca's US headquarters and conducted a review of US-reported information in the AstraZeneca Annual Report. Bureau Veritas reported that AstraZeneca US had responsible business governance processes in place, as well as appropriate systems to capture responsible business and reputational risks at both the functional and central level through the activities of the RBT and LET. Bureau Veritas also stated that a strong understanding and commitment to responsible business was demonstrated by AstraZeneca US leaders. Also noteworthy were our well-structured communication links between US and global responsible business activities.

While we encourage employees to report potential issues to their manager, our employees can also report possible violations of law and policy by using our anonymous (if desired) Code of Conduct Helpline, as well as make a report to a member of the Compliance and Ethics Department, Human Resources or the Legal Department. We handle and investigate each report on an individual basis and take consistent disciplinary action to address any inappropriate conduct. To support our internal Openness program, consolidated results of all completed investigations are provided to employees on a quarterly basis to reinforce the fact that all alleged violations will be investigated and appropriate action will be taken.


Because compliance is a dynamic concept, AstraZeneca performs risk assessments on the overall effectiveness of our Compliance Program at least annually. As part of this assessment, AstraZeneca may modify aspects of the program to make it more effective.

Ensuring Responsible Business Translates

throughout Our Supply Chain

We apply responsible business principles to suppliers as well as ourselves. We formally inform all AstraZeneca suppliers of our responsible business principles and reinforce their adherence. We also provide new suppliers with specific details about our policies and expectations, the language of which has been added to all AstraZeneca US contracts. We work closely with our key suppliers to review their responsible business compliance, identify issues of concern, encourage and facilitate continuous improvement and, where necessary, seek alternative suppliers whose performance and commitment are consistent with our established principles.

AstraZeneca developed a process called Responsible Procurement to ensure we integrate our Code of Conduct requirements into our decisions and work only with contractors who embrace standards of ethical behavior consistent with our own. Responsible Procurement is a risk-based approach to ensure that we consistently apply the appropriate due diligence to our supplier selection and management processes.



Responsible Business, Healthier Company

Creating a Healthy Workforce

Healthy people make a healthier company. That's why AstraZeneca is committed to making sure we give our employees tools they can use to live healthy lives.

In 2008, AstraZeneca began taking a closer look at our confidential self-reported health assessment data and conducted a study to compare how the information employees provided on their annual Health Assessments compared to their actual health claims. We discovered that employees' self-reported health conditions and medication usage matched their actual health claim data more than 90 percent of the time. More specifically, the findings included a correlation of 94 percent for medical conditions and 96 percent for prescription drug coverage. This information validated the use of a Health Assessment to obtain accurate information about an employee's health condition, medication use and health screening information. The health information was collected by the Mayo Clinic.


The ability to obtain accurate employee health information ensures that we can make careful decisions on how to spend their health plan dollars on disease management, prescription management and preventive care benefits. The data provided from this process will help AstraZeneca make decisions about the types of health promotion programs we should offer in the workplace and through our health plans. To date, AstraZeneca offers 100 percent coverage for preventive and wellness services, has reduced prescription costs for specific chronic conditions and, in 2008, worked to reach full mental health and substance abuse parity in our health plans.

AstraZeneca was one of the only pharmaceutical manufacturers to publically endorse the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act. AstraZeneca has provided treatment options

for mental illnesses for more than 10 years. We know that one in five American adults suffer from mental illness and far too many are denied access to the kind of care they need to lead healthy, productive lives. Our own benefits policies reflect our belief that mental health care is as important as other medical needs. Federal legislation supported by AstraZeneca passed in October 2008 will require employer-sponsored health plans to offer the same level of mental health care coverage as they do for medical and surgical benefits in October of 2009.

This year, AstraZeneca also offers disease management programs to our employees, retirees, and their family members, at no cost:

- **Health eGoals™** is an interactive, on-line program for managing cholesterol and hypertension in partnership with Health Media. Participation is voluntary and those who join receive guidance, tools, virtual coaching and tailored strategies designed to help with medication and weight management, stress reduction, smoking cessation and other personalized strategies
- **HealthMapRx™** is a pilot program offered to diabetics who reside near our US headquarters (Delaware, New Jersey, Pennsylvania or Maryland.) Participation is also voluntary, and those who join engage in an educational/health monitoring program with local pharmacists to learn how to manage their condition. AstraZeneca partnered with the American Pharmacists Association Foundation to implement this new approach to improve patient healthcare



Responsible Business, Healthier Company

In 2008, we continued our long tradition of offering on-site screenings for cholesterol, breast cancer and prostate cancer. For the second year in a row, AstraZeneca partnered with an external provider to offer our employees a point-based incentive program aimed at improving participation in healthy activities. More than 1,500 employees participated in the program during 2008, earning points by taking part in company-sponsored health and fitness activities, many of which were offered online through the Mayo Clinic. Popular activities include weight loss and smoking cessation programs, walking activities and other programs at our fitness center, health fairs and “lunch and learn” lectures. Annual health risk assessment data shows that the number of health risks for regular participants in this program was significantly reduced compared to non-participants. In addition, regular participants also demonstrated lower healthcare costs and disability rates.

AstraZeneca employees also support health and wellness activities offered by many of the organizations we partner with throughout the year, such as walks and runs sponsored by the American Cancer Society, the American Heart Association and the Susan G. Komen Foundation.

AstraZeneca is proud to have received recognition for our innovative and forward-thinking solutions to improve employee health. In 2008, the National Business Group on Health awarded AstraZeneca US with its Best Employers for Healthy Lifestyles award, Gold level, “to acknowledge and reward those employers who have responded to the urgent need to improve their workers' health, productivity and quality of life.”

AstraZeneca also received CEO Gold Standard Rec accreditation by the CEO Roundtable on Cancer for its ongoing promotion of employee cancer-prevention


At AstraZeneca, we encourage a diverse, inclusive and flexible work environment, and this commitment has been recognized by several organizations. In 2008, AstraZeneca was recognized as:

- One of the “100 Best Places to Work” by *FORTUNE* magazine
- Among the “100 Best Companies for *Working Mothers*” by Working Mother magazine.
- In the top 10 companies listed in the National Association for Female Executive’s Top 50 Companies for Executive Women
- One of the 20 best companies according to *Diversity MBA*
- One of the 100 Best Adoption Friendly companies by the Dave Thomas Foundation
- *Conceive* magazine’s Top 50 Companies for Fertility and Adoption Benefits

initiatives. In 2005, AstraZeneca was among the first six organizations to receive Gold Standard Accreditation, which recognizes the actions AstraZeneca takes to promote cancer prevention, early cancer detection and access to quality cancer care for all employees and their dependents.

AstraZeneca offers a wide range of health resources and programs to encourage employees to have a high level of involvement in their personal health management. Our reaccreditation demonstrates AstraZeneca’s ongoing commitment to the promotion of employee cancer-prevention initiatives.”

– **Joseph Henry MD,**
*Executive Director, Safety,
Health and Environment*



Responsible Business, Healthier Company

Nurturing a Diverse Family of Employees

Our success as a company depends on our ability to attract, retain and inspire the very best people. To do this, we must respect, embrace and derive strength from all that makes individuals unique. We must also offer work/life effectiveness programs, policies and resources to help our employees manage their work and personal responsibilities. These programs support our top priority: promoting equal opportunity and building, encouraging and supporting a more diverse family of employees.

For example, women hold key leadership positions in our company, including the vice presidents of sales, corporate communications, external medical relations, human resources North America and customer product support and business services. As of the end of 2008, two of the eight US Leadership Team members and our US compliance officer were female. More than half (54 percent) of newly hired employees were women. AstraZeneca also employs a diverse sales force. In 2008, 24 percent of new sales hires were minorities and 58 percent were women.

Creating an inclusive culture also is a critical component of a healthy company. AstraZeneca offers a range of employee network groups, which provide forums for AstraZeneca employees from all walks of life to discuss and act upon issues and topics that are timely and important to employees.

In 2008, AstraZeneca employees were members of 14 active Employee Network Groups, including:

- ALSHEA: a Middle Eastern Employee Network Group
- AstraZeneca African American Network
- AstraZeneca Chinese American Network
- AstraZeneca Eldercare Employee Network
- AstraZeneca Military Support Community
- AstraZeneca South Asian Employee Network
- Gay, Lesbian or Bisexual Employee Network
- Hispanic Employee Network Group

- Pan Asian Coalition for Excellence
- Special Needs Advocates for AstraZeneca
- Succeeding Through our Ability to Gain from Experience
- AstraZeneca Network of Women
- AstraZeneca Women Field Leadership Network
- Working Parents Network and Parent Employees at AstraZeneca

Promoting Work/Life Balance

Work/life balance is vital to our employees' health and well-being. AstraZeneca offers a number of work/life effectiveness programs, policies and resources that help our employees manage their work and personal responsibilities. We promote a variety of flexible work arrangements, resource and referral programs, and dependent care initiatives. In addition, we offer AstraZeneca employees and their families a range of services designed to promote emotional health, work/life balance and wellness. One example of this is the AstraZeneca Child Development Center adjacent to our Wilmington, Delaware, US headquarters. This facility provides child care for more than 300 children ages infant to six.

Other employees benefit from AstraZeneca-sponsored programs for school-aged children, such as holiday child care programs and summer camp. As part of the "Just in Time Care Program," our employees are eligible for 10 days of back-up care for their children and elder family members; we subsidize 90 percent of the cost. In 2008, we provided more than 8,000 days of care for employees and their families. The company also supports employees who provide eldercare through

the Resource and Referral program that includes geriatric care management to assess needs and create a care plan.



Responsible Business, Healthier Company

Developing the Best Talent

Developing our next generation of leaders is a top priority at AstraZeneca. One of the best ways to do this is to make sure our people have opportunities to keep learning and honing their skills. Our AstraZeneca University (AZU) delivers more than 400 online and classroom courses, spanning a wide range of functional areas, to AstraZeneca employees and their families. Each month, approximately 3,500 employees participate in AZU. In addition, we provide tuition reimbursement assistance for our employees who choose to pursue external training and development in the fields of business and science.

In the coming year, we will track our responsible business performance to improve our processes and identify areas for future growth. Our Responsible Business Team will be monitoring objectives against our Action Plan drafted for 2009/2010 in the areas of diversity and corporate governance and compliance, among other categories. Our plan will help us maintain and develop a healthier company.

Looking ahead: Our goals for 2009 and beyond ...

- Introduce “Responsible Business” scorecard to track performance
- Recruit, develop and retain an increased number of women and minorities
- Focus on age as part of Diversity program and increase the engagement of mature workers



Responsible Business, Healthier People

As a leader in the US pharmaceutical industry, we believe it is our responsibility to foster a constructive, open and informed dialogue between patients and physicians. Our willingness to listen, together with the appropriate use of consumer marketing and responsible communication with patients, physicians, regulators and other key stakeholders, is vital to our ongoing commitment to helping people stay healthy and live longer lives.

Making a significant difference in people's health requires that we act meaningfully. We help by providing doctors and patients with the clearest, most objective information available, and ensuring that our sales and marketing personnel adhere to the highest ethical standards.

This year AstraZeneca made significant efforts to advance our commitment to transparency. We believe providing information to the public about our company, our products and how we do business is integral to improving patient health. In May, we helped to improve patient health by ensuring physicians are knowledgeable about our products and patient assistance programs, and by providing physicians with timely, relevant information that enables them to make the best treatment decisions for their patients. In addition, we revised AstraZeneca policies to reflect the new PhRMA Code on Interactions with Healthcare Professionals, and worked to educate our employees about the new company and industry policies.



2008 Health Highlights:

- Registered more than 800 clinical trials and published results of more than 500 trials
- Extended scope of clinical trials disclosure to include information about the registration and results of ongoing AstraZeneca-sponsored clinical trials for all products in all phases
- Received the "Corporate Circle Award" from the National Medical Association for serving as an outstanding partner committed to the health of African Americans
- Revised AstraZeneca policies to align with standards in the revised PhRMA Code on Interactions with Healthcare Providers
- Pursued several new product-security efforts to protect patients from counterfeiting and ensure they receive genuine medicines

A Responsible Approach to Marketing

We make it a priority to provide objective, balanced information about our products that comply with federal regulations and conform to the full Food and Drug Administration (FDA) approved prescribing information. We respect our patients' privacy and ensure that all of our programs are Health Insurance Portability and Accountability Act (HIPPA) compliant.

We understand that ethical, transparent marketing practices begin with educating our employees about stringent company and industry policies that ensure patients and physicians receive balanced information. We comply with the PhRMA Code on Interactions with Healthcare Professionals, which PhRMA adopted in 2002 and revised in 2008 to ensure that interactions between research-based pharmaceutical companies and healthcare providers are ethical and responsible. AstraZeneca policies were revised in the fourth quarter of 2008 to align with the revised PhRMA Code.

Responsible Business, Healthier People

The revised code went into effect on January 1, 2009, and includes the following changes:

Promotional items: In 2009, AstraZeneca's US sales representatives will no longer distribute "reminder" items such as pens, pads of paper, tissues and hand soap as part of sales calls to healthcare providers. AstraZeneca sales representatives may still offer items designed for the education of patients or healthcare providers if they are not of substantial value, are offered infrequently and comply with all applicable laws. Examples include teaching models of organs or arteries, adherence materials, or patient assistance information.

Meals: Also in 2009, AstraZeneca US sales representatives no longer will take healthcare providers to restaurants for meals. They still will be permitted to bring modest and occasional meals into healthcare offices and hospital settings for informational presentations, and provide them in conjunction with speaker programs that are held in public venues. These presentations will provide up-to-date information on AstraZeneca products and other issues that affect patient care; ideally, these presentations will take place during lunchtime to minimize time away from patients.

Sponsorship of Meetings: AstraZeneca will continue to support Independent Medical Education (IME) events for healthcare professionals. As in the past, this support will be in the form of a grant to an independent provider and AstraZeneca will provide no guidance regarding the content or faculty. AstraZeneca will also not sponsor meals at these events.

In addition, AstraZeneca also adheres to the PhRMA guidelines on entertaining healthcare providers; using prescriber data; and training sales representatives to conduct themselves ethically and with integrity. Please visit <http://www.phrma.org> for more information on the new code.

To assist sales managers with internal adherence to our ethical standards, we operate a Policy Action Line. The Policy Action Line enables employees with questions about AstraZeneca policies and practices to speak with compliance and ethics leaders who deliver comprehensive guidance regarding the proper pursuit of business objectives. Our Code of Conduct Helpline encourages ethical business practices by providing a forum for employees to report any concerns they may have.

In addition, to help employees obtain guidance or report information, AstraZeneca has partnered with Ethics Point to provide an easy, confidential, and anonymous (if preferred) way to seek guidance on or report activities that may involve inappropriate conduct or violations of the AstraZeneca Code of Conduct. To ask questions or raise concerns, employees are encouraged to go to AZEthics.com or call 866-99ETHICS (1-866-993-8442).

To ensure clear understanding of our policies and guidelines, all sales and marketing employees and designated external resource personnel are required to complete annual training on our Code of Conduct and marketing- and sales-related AstraZeneca business policies. In addition, we provide training programs for third-party vendors to ensure their understanding and adherence to our policies.



Responsible Business, Healthier People

Helping Healthcare Practitioners Improve Patient Care

At the foundation of our marketing efforts is the principle that a healthcare practitioner's care should be based solely on the patient's medical needs and that professional's medical knowledge and experience. Our job is not only to develop products to better serve public health, but also to deliver information that allows healthcare professionals to provide the best care for their patients.

As such, we are committed to providing healthcare practitioners with important information about our products. We aim to conduct these efforts, in addition to our relationships with healthcare practitioners, in an ethical manner that is consistent with our internal ethical standards, as well as in full compliance with the laws and regulations that govern the healthcare community in the United States.

We monitor interactions with healthcare practitioners through our managers and our compliance and ethics leaders. Our Group Internal Audit function conducts audits of sales and marketing practices. These programs support our other systems in place for identification and discipline of breaches.

Marketing Products Ethically to Patients

At AstraZeneca, patient safety is our top priority, and we are committed to ensuring that our sales and marketing efforts are ethical, effective and compliant with all laws, regulations and our own high standards. We believe that consumer marketing, when done appropriately, shifts the emphasis toward prevention and early treatment by enabling access to health information and encouraging patients and family members to ask informed questions of their physicians. Through our consumer marketing, we hope to enable patients and their caregivers to work with their healthcare providers to make important choices and sustain lifestyle changes that result in greater health.


Like other pharmaceutical companies, we distribute information through a variety of consumer marketing channels, including magazines, newspapers, television and the Internet. Our intent is to better inform consumers about medical conditions, treatment options and approved use(s) of our products.

The information found in our consumer marketing is a result of listening to and learning from physicians, patients, caregivers, healthcare professionals and policy makers. We strive to deliver accurate, balanced and timely information about our prescription medicines and the conditions they treat to the appropriate patients.

To help ensure that consumers understand safety information about our products, we introduced five easy-to-read Consumer-Friendly Brief Summaries to accompany product advertisements. Our Brief Summaries direct consumers to discuss the safety information about our products with their healthcare providers. We also introduced two Brief Summaries in Spanish to reach a broader multicultural population.

AstraZeneca US works closely with PhRMA to establish ethical practices across the industry, and we employ both industry-wide standards and our own policies to guide our sales and marketing conduct.

We continue to abide by PhRMA's Guiding Principles for Direct-to-Consumer Advertisements About Prescription Medicine as a supplement to our own consumer marketing guidelines. However, we view industry standards as a floor, not a ceiling. When we see a need for even stricter policies or guidelines, we call for them. AstraZeneca was one of the first companies to propose mandatory FDA review of broadcast advertisements before they aired, and led the industry association in working with the FDA to improve DTC advertisements.



Responsible Business, Healthier People

AstraZeneca Consumer Advertising Principles

We recognize television and radio are powerful media that must be used responsibly. We are committed to creating television advertisements that are educational in content and serious in tone. With that in mind, AstraZeneca has instituted guidelines to govern our DTC advertisements:

- Ensure an appropriate balance between the benefit and risk information we deliver and clearly communicate such information so patients can have better-informed conversations with their doctors
- Provide accurate and clear information about medical conditions and the treatment options we offer in a straightforward and responsible manner
- Provide patients who are unable to afford our medicines with information on patient assistance programs
- Remind patients of the necessity of talking with their doctors about which treatment is appropriate for them

AstraZeneca is the first company to use all televised product advertising to provide patient assistance information for those unable to afford our medicines. In addition, before distribution, all television advertising is reviewed by senior management for compliance with the aforementioned guidelines and principles.

Putting Patient Safety First

AstraZeneca is a research-based pharmaceutical company whose corporate, ethical and regulatory responsibility is to put the health of [patients first](#). This is achieved by continual monitoring of AstraZeneca medicines. It is well known that all medicines have risk associated with taking them. In order to manage this risk, the benefits of a medicine must be weighed against its side effects and the acceptable level of risk decided upon by regulators who approve it for marketing, by

healthcare professionals who prescribe it, and, ultimately, by patients who consume it. AstraZeneca aims to understand and communicate the risk/benefit profile of our products to regulators, health care professionals and patients through continuous assessment in order to ensure the safety of our patients.

Providing Full, Transparent Disclosure on all Clinical Trials

As part of our continued commitment to provide patients and healthcare professionals with meaningful information about our products, we extended the scope of our clinical trial disclosure in 2008 to include information about the registration and results of AstraZeneca-sponsored clinical trials for all products in all phases, including marketed medicines, drugs in development and drugs whose further development has been discontinued. These disclosure requirements are laid out in our global [Bioethics Policy](#), compliance is mandatory across the Company.



Responsible Business, Healthier People

We make details about our clinical trials available on public Web sites and, by the end of 2008, we had registered more than 800 trials and published the results of more than 500 trials. Our commitment to publishing results, irrespective of whether they are favorable or unfavorable to AstraZeneca, remains unchanged. To ensure full transparency, we take the following steps to publish results of all our clinical trials:

Clinical trials are registered on the [US National Library of Medicine's](#) Web site within 21 days of the first patient being enrolled in a trial. Basic information is also posted on our own dedicated [Web site](#), which contains information dating back to 1992.

Results of trials with marketed medicines are published within one year of completion. Results of trials with medicines in development are published within 30 days of first regulatory approval for the new medicine. When a medicine in development has been discontinued, results are published within one year of the public announcement of the decision, unless analysis and interpretation of the data are not sufficiently complete, in which case we post a brief explanation for the delay and the anticipated date when the results will be posted. In situations involving marketed medicines in which we believe there is good cause to delay posting results, we will seek necessary approval according to applicable law. Where approved, we post a brief explanation for the delay and the anticipated date when the results will be posted.

Results are posted on our clinical trials [Web site](#), the [US National Library of Medicine's](#) Web site, and, for US-approved medicines, the [PhRMA](#) Web site. Information is also provided on the International Federation of Pharmaceutical Manufacturers and Association's portal, which provides a single entry to trial registration and results information across the pharmaceutical industry.

Because we operate in an ever-changing environment, we closely monitor developments and advances in this area so that AstraZeneca remains at the forefront of best practice in clinical trial transparency.

Increasing Value in Healthcare

AstraZeneca is fully engaged with organizations whose goals are advancing drug development and increasing value in healthcare. We are committed to ensuring that patients and physicians have the best information available to support their treatment decisions. In the emerging area of biomarker research, AstraZeneca is engaged with the FDA and the Critical Path Institute as members of the Biomarker Consortium and the C-Path Predictive Safety Group. We participate in the Institute of Medicine (IOM) of the National Academies of Science in the Evidence-Based Medicine Roundtable, the IOM Translating Genomics into Health Round Table and the IOM Forum on Drug Discovery, Development and Translation in an effort to help transform the way evidence on clinical effectiveness is generated and used to improve health and healthcare in the US.

Comparative Clinical Effectiveness Reviews

AstraZeneca facilitates and supports the appropriate diagnosis of disease and treatment opportunities for patients. For example, clinical evidence from randomized controlled trials and health economics studies are provided as part of the Effective Health Care initiatives sponsored by the US Health & Human Services Agency for Health Care Research and Quality (AHRQ). Results of AHRQ studies are shared internationally and across peer-networks to identify the most current diagnostic and treatment opportunities.



Responsible Business, Healthier People

Ensuring Patients Have Access to Authentic, Safe Products

AstraZeneca patient safety employees work worldwide to ensure that the risk profiles of AstraZeneca compounds are accurately defined. For each AstraZeneca medicine, we designate a Global Patient Safety Physician, who is accountable for monitoring the safety profile of a medicine from the first time it is exposed to humans in clinical research through regulatory approval and into treatment of patients in medical practice.

The result of this effort is that over 90 percent of the changes to the Core Safety Information for a medicine are generated within AstraZeneca. The Core Safety Information is the basis for risk information that is communicated to researchers through the Investigator's Brochure for medicines in development and to healthcare professionals through product labeling for approved medicines.

Drug counterfeiting is another growing challenge in the United States, as the number of counterfeit drugs that make it to the American marketplace increases. The World Health Organization estimates that counterfeit drugs, a term that includes fake, substandard, adulterated, and mislabeled pharmaceuticals, comprise about 10 percent of the global drug supply. Not only is the counterfeiting of pharmaceutical drugs criminal, but it also threatens to harm the health and wellness of patients. AstraZeneca uses a number of product-security efforts to help ensure that patients receive genuine medicines. For example:

- AstraZeneca uses both overt and hidden security features on packaging of certain products to enable rapid identification of counterfeit product
- AstraZeneca monitors and assesses risks to its brands and takes appropriate action regarding anti-counterfeiting features on its packages and medicines

- AstraZeneca works closely with wholesalers on strategies that promote a safe and secure supply of medicines
- AstraZeneca continues to investigate new technologies to help prevent misuse of products by enabling more precise tracking of shipments


Promoting Workplace Safety

Worker safety is one of the highest priorities for our company. Whether an employee works in an office, laboratory, packaging facility or automobile, we must promote the highest standards of safety. From formal processes for risk management to grass-roots initiatives for process improvements, we empower our employees to take ownership of their own safety and the safety of their coworkers.

With a sales fleet of around 6,500 vehicles in the US, driver safety is a high priority and managed through our Road Scholars program. In 2008, we made two improvements to the program. We began a behind-the-wheel training course designed specifically to help district sales managers become more effective coaches of driver safety. In addition to hands-on experience, the course content includes instruction on how to formulate constructive and effective commentary for their employees who drive on the job. We also added an annual driver safety performance objective, which has resulted in greater driver safety awareness and leadership accountability within the program.

In addition all drivers and their managers are required annually to recertify their understanding of our Motor Vehicle Safety & Usage Policy.

Thanks to our safe drivers, preventable collisions decreased by 14% from the previous year, and moving violations went down by 50%.



Responsible Business, Healthier People

In 2008, AstraZeneca's revised its guidelines to be fully compliant with the new PhRMA Code, and in 2009 those guidelines are being implemented. The revised code complements our philosophy that any interaction with healthcare providers should be about providing information that helps them decide on the right medicines, for the right patients, at the right time. In the future, AstraZeneca will continue to support new policies that benefit patient care.



Looking ahead: Our goals for 2009 and beyond...

- Explore ways to increase diversity in clinical trials
- Continue to implement transparency policy in the US areas of public policy, compliance, clinical trials, political contributions, medical education grants, contributions to nonprofit organizations and FDA post-marketing study commitments
- Ensure accurate and timely product safety and adverse event reporting

Responsible Business, Healthier Communities

At AstraZeneca we believe that all people should have affordable health insurance and prescription drug coverage. It is an ambitious but needed goal, and there is a lot of work to do, but we are dedicated as a company to collaborate and partner with others to make this goal a reality.

Improvements in medicine have allowed people to live healthier, longer, and more productive lives. Yet, 130 million Americans suffer from chronic diseases like diabetes and heart disease. In addition, more than 47 million Americans do not have health insurance, leaving them without routine medical care and access to the preventive care to help head off major health problems. Access to quality care must be a primary focus of healthcare reform and preventing chronic diseases.

When evaluating healthcare reform plans, there are four main principles AstraZeneca believes are necessary, including:

- The promotion of market competition that leads to improved health outcomes.
- The enhancement or maintenance of patient safety
- The expansion of coverage for the uninsured.
- The fostering of innovation and protection of intellectual property.

Furthermore, when treatments don't reach a population—no matter how effective our drugs may be—we haven't made a mark when it comes to improving patient health. We recognize that our responsibility goes beyond making meaningful medicines to making them available to those in need. For the last thirty years, AstraZeneca has offered patient assistance programs side-by-side with our medicines to uninsured individual and families earning up to three times the federal poverty level. This year we provided more than \$600 million in AstraZeneca medications to those in need.

In keeping with our culture of transparency, we began to publish biannual reports of our contributions to nonprofit organizations, as we believe it is important to be open about what we are doing to make a meaningful difference to patient health. This year, AstraZeneca donated \$41.4 million to non-profit organizations across the US.

Improving Access to Medicine

AstraZeneca recognizes that providing affordable and accessible healthcare to uninsured and underinsured Americans is critical to building healthy communities. We support several initiatives to improve individuals' access to the medicines they need by including many of our treatments in federal and state patient assistance programs, as well as programs run by various health plans. In addition, AstraZeneca offers a variety of assistance programs that provide eligible participants with medicines free of charge or at significant savings. AstraZeneca is also the first company to use all televised product advertising to provide information on programs available to those unable to afford their medicines.



What can one pharmaceutical company do to help more than 440,000 people who need help affording their medication?

A lot. We're AstraZeneca. Makers of NEXIUM®, CRESTOR®, SYMBICORT®, and other innovative medicines for people. We know our responsibility goes beyond making meaningful medicines—to making them available to those in need. If you take any of our medicines, and you can't afford them, you may be surprised to learn that there's someone who may be able to help: AstraZeneca. We have offered patient assistance programs side-by-side with our medicines for three decades. In the last six years, AstraZeneca has given away more than \$3 billion worth of medicines to people without prescription insurance. In 2008, AstraZeneca helped nearly 440,000 people fill 2.7 million prescriptions resulting in more than \$600 million in savings to patients.

At AstraZeneca, we may not have all of the answers—but we do know how we treat people is as important as the medicines we make.

NEXIUM, CRESTOR and SYMBICORT are registered trademarks of the AstraZeneca group of companies. ©2008 AstraZeneca Pharmaceuticals LP. All rights reserved.

For more information,
call 1-800-AZandMe
or visit AZandMe.com

AstraZeneca 

Creating Healthier Lives for Uninsured and Underinsured People

Since 1978 AstraZeneca has been helping patients who cannot afford their medications through its AstraZeneca Patient Assistance Program. AstraZeneca was one of the first companies to extend its patient assistance program to people who earn 300 percent of the Federal Poverty Level, and during 2008, was one of only two pharmaceutical companies at that threshold. During the last six years, AstraZeneca more than \$3 billion of medicine to people without prescription insurance.

AZ&Me™ Prescription Savings programs

AstraZeneca has a suite of patient assistance offerings through our AZ&Me™ Prescription Savings programs. In 2008, we helped 440,000 people fill 2.7 million prescriptions, resulting in more than \$612 million in savings for patients.

Although the US median household income is \$46,000, AstraZeneca's eligible annual income to participate in our AZ&Me™ Prescription Savings programs is \$60,000 for a family of four (\$30,000 for an individual, \$40,000 for a couple).

AZ&Me™ Prescription Savings program for people without insurance

For more than 30 years, AstraZeneca has provided medicines to people without prescription drug coverage. This program enables those meeting the eligible annual income levels to access their AstraZeneca medicines at no cost, with their medicines mailed directly to their home or their healthcare provider.

AZ&Me™ Prescription Savings program for healthcare facilities

AstraZeneca partners with healthcare facilities in an effort to help address the issue of access to prescription medicines for uninsured and underinsured individuals. In 2007, AstraZeneca reopened to new enrollees its AZ&Me™ Prescription Savings program for healthcare

2008 Community Highlights:

- Continued to increase public awareness of patient assistance programs by including affordability reference in direct-to-consumer advertising
- Helped 440,000 people fill 2.7 million prescriptions
- Implemented tools and systems to allow public greater access and transparency around our charitable contributions
- Donated more than \$3 billion in medicine for people without prescription drug insurance over the last six years
- Supported 15 new American Cancer Society Patient Navigator sites

facilities to provide medicines free of charge to free clinics, community health centers and hospitals that serve uninsured individuals. This program has helped hundreds of thousands of patients. Participating facilities receive bulk medications sent directly to their on-site pharmacies to use for eligible patients. This program enables eligible patients to receive the AstraZeneca medicines they need at the same place they receive their medical care.

AZ&Me™ Prescription Savings program for people with Medicare Part D

The AZ&Me™ Prescription Savings program for people with Medicare Part D is designed to provide significant savings to qualified people enrolled in Medicare Part D prescription drug coverage plans who are having difficulty affording their AstraZeneca medicines.



Responsible Business, Healthier Communities

Fostering Healthier Lives for Senior Citizens

The Medicare Prescription Drug Improvement and Modernization Act of 2003 brought about the single biggest change in healthcare delivered by the US government in nearly 40 years. In 2006, the government made prescription drug coverage available to everyone with Medicare, regardless of their income or health status. This benefit, called Medicare Part D, affected more than 43 million Americans.

In addition to providing savings to those enrolled in the AZ&Me™ Prescription Savings program for people with Medicare Part D, AstraZeneca is engaged in a number of Medicare outreach and education efforts. Through an initial grant of \$10 million, we supported *My Medicare Matters™*, a community-based national education campaign sponsored by the National Council on Aging and the Access to Benefits Coalition. In 2008, this campaign worked with community organizations to update materials and provide user-friendly tools, materials and training for community organizations so they can better assist others.

Improving Access to Medicine for People Around the World

Globally, AstraZeneca is collaborating with non-governmental organizations, foundations and other groups to build healthy communities in the developing world. One of our key initiatives is working with other organizations to help vulnerable communities combat tuberculosis, and we have a research facility dedicated to finding a new, improved TB treatment.

In 2008, AstraZeneca continued its work with AmeriCares, an international relief organization that has delivered more than \$8 billion of aid to people in 137 countries over the past 25 years. In 2007 and 2008 combined, AstraZeneca donated \$25.5 million

worth of products to AmeriCares. We also support the organization's Medical Outreach Program, which donates medical products to qualified US healthcare professionals traveling overseas to care for needy and underserved people in more than 80 countries.

AstraZeneca and AmeriCares also initiated a long-term project with Hope Worldwide's Sihanouk Hospital Center of Hope in Phnom Penh to combat breast cancer in Cambodia. Through this exciting three-year commitment, we are aiming to make more diagnostic services and treatments available to more patients, raise public awareness about breast cancer and build the capacity of healthcare providers to diagnose and treat this deadly disease.

Raising Health Awareness in Communities Across the US

When we work with partners in local communities, we are more successful in helping people live longer, healthier lives. That's why AstraZeneca supports an array of community programs and initiatives with nonprofit organizations that is primarily dedicated to disease awareness and prevention, education and research, improving access to healthcare. In 2008, AstraZeneca donated \$41.4 million to nonprofit organizations across the US. The following examples highlight the results of our community support and commitment to raising health awareness and improving patient health.



Responsible Business, Healthier Communities

Preventing Heart Disease

AstraZeneca has a more than 50-year legacy of discovering and developing some of the industry's most innovative and effective cardiovascular therapies.

The dedication of AstraZeneca to improve patient lives goes beyond treatment and research to include patient education programs about heart disease. In 2008 we:

- Launched the **US AGAINST ATHERO** campaign (UAA), a bilingual, national education program to raise awareness of atherosclerosis—the buildup of plaque in the arteries—and how this chronic, progressive disease can lead to heart attack, stroke and other dangerous consequences. In 2008, the “Artery Explorer,” an interactive motion simulator that helps people visualize atherosclerosis, traveled the country reaching more than 79 million people through events and media stories. Nearly 100 ally organizations joined AstraZeneca to support the UAA mission of educating consumers about atherosclerosis
- Received the **American Heart Association's 2008 Platinum “Fit-Friendly Company”** award for the second year in a row. The award recognizes companies that are taking a leadership role in corporate wellness initiatives. AstraZeneca was the first corporation to receive such an award from the association in 2007 and has pledged to continue to inspire other companies to improve their heart health by adopting employee health and wellness programs. Additionally,

through collaborations with leading advocacy and patient-support organizations, AstraZeneca:

- Is the national pharmaceutical sponsor of Start!—the American Heart Association's (AHA) national movement to encourage all Americans to live longer, stronger lives by taking up walking and other healthy habits in and out of the workplace
- Is the first corporate sponsor of the Super Weekends program, an initiative hosted by the Association of Black Cardiologists, Inc. (ABC) focused on training community leaders about cardiovascular health and educating their local communities
- Became the first corporate sponsor of the Hispanic Cardiologists Network, a leadership group of Hispanic cardiologists led by the National Alliance for Hispanic Health and American College of Cardiology. The group focuses on identifying key actions for advancing cardiovascular health in Hispanic populations
- Partnered with the League of United Latin American Citizens to educate the Hispanic community on the impact of cardiovascular disease



US ★ AGAINST ★ ATHERO™
Fighting Atherosclerosis with Knowledge

Supporting Cancer Patients and their Families

As one of the leading makers of oncology medicines, AstraZeneca understands the challenges of cancer. To improve patient outcomes and help people overcome challenges that are critical for living longer, healthier lives, we joined forces with the American Cancer Society to help fund the Patient Navigator Program, which connects individuals affected by cancer to navigators who will help them throughout their cancer experience. With AstraZeneca's funding, the American Cancer Society will accelerate the opening of 50 new Patient Navigator sites in the next five years. Fifteen AstraZeneca-sponsored sites were available at cancer centers by the end of 2008.

AstraZeneca also supports a program that offers a home away from home for cancer patients and their families who must travel to receive treatment. The AstraZeneca Hope Lodge Center opened in Boston in October of 2008 and Philadelphia in May of 2009.

In addition, AstraZeneca launched the Cancer Study Locator service in collaboration with EmergingMed. The is confidential and free service helps patients, physicians and caregivers identify cancer studies throughout the United States and Canada that may be appropriate based on a patient's specific diagnosis and treatment history.

Matching and referrals are based on answers to several questions that help identify studies for which patients may be eligible. Upon request, Clinical Trial Specialists from EmergingMed can provide additional information about the studies' and can help facilitate contact with the study sites.

Reducing Healthcare Disparities for African Americans and Hispanics

Physicians with diverse backgrounds are essential to clinical trials because they understand the treatment needs of diverse patients. In a 2004 survey by Harris Interactive, only 13 percent of US physicians engaged in clinical trials were ethnically diverse. To bring more diverse physician and consumer participation in clinical trials, AstraZeneca continued its work with the National Medical Association (Project IMPACT) and the Interamerican College of Physicians and Surgeons (Hispanic Research Network).

In 2008, the NMA recognized AstraZeneca with its "Corporate Circle Award," which is given only to companies who serve as outstanding corporate partners and are committed to the health and wellness of African Americans. AstraZeneca was also the only pharmaceutical company to receive three awards at the NMA's 2008 Annual Convention & Scientific Assembly.

Fighting the Stigma of Mental Illness

AstraZeneca continued its support of one of its signature initiatives, the National Alliance on Mental Illness' Connection Recover Support Group, launching programs in more than 30 states by the end of 2008. AstraZeneca also continued its co-sponsorship with The JED Foundation, the leading nonprofit college suicide prevention charity.



Responsible Business, Healthier Communities

Making a Life with Asthma Easier

In 2008, AstraZeneca and The American College of Allergy, Asthma and Immunology (ACAAI) provided free asthma screenings using spirometry in 250 communities nationwide. Now in its 12th year, the Nationwide Asthma Screening Program has screened more than 120,000 people and referred over 50 percent of them to their family physician for further evaluation. AstraZeneca is also the national sponsor of The American Lung Association's "Breathe Well, Live Well: An Asthma Management Program for Adults."



The Center for Information and Study on Clinical Research Participation

AstraZeneca supported the Center for Information and Study on Clinical Research Participation (CISCRP) with Uniworld to develop general clinical trial awareness and educational materials as well as those targeted at asthma and other respiratory diseases for the African-American and Hispanic population.

Congressional Black Caucus Foundation: Black Health Empowerment Project

AstraZeneca's support of the Congressional Black Caucus Foundation health education programs is another example of our commitment to making a difference in healthcare within communities across the nation. We support CBCF's initiative, the Black Health Empowerment Project (BHEP), a program designed to educate African Americans about the relationship between obesity and the chronic health conditions that disproportionately plague diverse and minority communities. Although awareness of the issues related to obesity is one of the principle goals of BHEP, the initiative also focuses on the importance of prevention and wellness. The program is intended to motivate African Americans to adopt healthy eating habits and participate in regular physical activity, as well as empower the African American community to take advantage of healthcare options available through their physician and other local healthcare professionals.


Since the inception of this program, it has reached 15 cities and brought health, nutrition and disease management education to more than 3,000 people. The BHEP consists of a one-day seminar focusing on nutrition, fitness and cardiovascular, asthma and prostate screenings. Health screenings are provided by community clinics, hospitals and health plans.



Responsible Business, Healthier Communities

Extending Our Care to the Communities We Serve

AstraZeneca strives to improve the health of the communities where our people live and work, particularly in our facilities' backyards of Delaware and Massachusetts. We provided more than \$1.6 million in contributions to organizations in and around our US headquarters in Delaware. The "AstraZeneca Healthcare Heroes" program has a number of volunteer activities including the AstraZeneca Ambassadors Program, which is a nationally recognized program by the Points of Light Foundation.



AstraZeneca in Delaware

Delaware, like other states across the country, is striving to help uninsured people in its state. Nearly 11 percent of Delaware's population—101,000 Delawareans—is uninsured and struggles to find access to health care, which has serious consequences for patient health.¹

AstraZeneca continues to support *Healthy Delawareans Today & Tomorrow*, a public-private coalition focused on helping people without health insurance learn about and gain access to the important free or low-cost healthcare services they need to lead healthier lives. In 2008, Delaware Governor Ruth Ann Minner declared April as the state's inaugural "Delaware Cover the Uninsured Month." The coalition engaged in grassroots outreach and a media campaign to spread the word about the many existing free and low-cost healthcare services available to the uninsured in Delaware. To date, the coalition has linked more than 13,000 uninsured Delawareans to free and low-cost healthcare services, medication assistance programs and other support services (e.g., translation, transportation, etc.)

As a co-leader of *Healthy Delawareans*, AstraZeneca has implemented or assisted with the following:

Healthy Delawareans Today & Tomorrow Coalition:

The coalition of 20 Delaware public and private organizations work together to create awareness of existing free and low-cost health services for the uninsured population in Delaware.

Healthy Delawareans Today & Tomorrow Healthcare

Resource Guide: Helps uninsured Delawareans find medical care, gain access to prescription assistance programs and support services (e.g., transportation to and from medical appointments). More than 120,000 guides have been distributed in English and Spanish.

AstraZeneca Healthcare Heroes: More than 100 AstraZeneca employees volunteered at Delaware healthcare facilities in 2008 as an expression of our personal commitment to the company's mission: helping to improve patient health.



Financial Support: In 2008, AstraZeneca continued to fund navigator positions for people to work as case managers at community health centers to help the uninsured access healthcare facilities and services.

Advancing Public Policy for the Uninsured:

Throughout 2008, AstraZeneca and the Delaware Public Policy Institute (DPPI) convened two summits identifying short-term coverage solutions for Delaware. As a result of the discussions, DPPI released a consensus report *Small State, Big Opportunity: Taking Action for the Uninsured* and a follow-up report. Both reports were distributed to more than 300 public and private sector leaders throughout the state.

¹University of Delaware Center for Applied Demography & Survey Research, Presentation to the Delaware Health Care Commission, February 5, 2009.

Responsible Business, Healthier Communities

AstraZeneca in Massachusetts

Across Massachusetts, AstraZeneca and its employees engage in activities and programs to improve patient health in their communities. Some key initiatives include:

Beyond the Medicine, Recognizing the Caregiver

AstraZeneca again sponsored the annual Compassionate Caregiver Award presented by the Boston-based Kenneth B. Schwartz Center, which offers training and support programs nationally for clinical professionals in multiple medical settings. This year marked the tenth anniversary of the Compassionate Caregiver Awards.

A strong partnership with the New England Division of the American Cancer Society

AstraZeneca's commitment to patients and the community is evident in the strategic and comprehensive partnership the company has with the American Cancer Society (ACS). AstraZeneca received the Community Health Partner of the Year Award at an annual event sponsored by the *Boston Business Journal*. The ACS, New England Division, nominated AstraZeneca for our significant and sustained support of their mission over the past six years. Programs that include the AstraZeneca Hope Lodge Center in Boston, Patient Navigator program at Massachusetts General Hospital, annual Flagship sponsorship for Making Strides Against Breast Cancer Walk, as well as the Research Challenge in New England with ACS and the Mass Biotech Council.

• AstraZeneca Hope Lodge Center in Boston

On October 29, 2008, the AstraZeneca Hope Lodge opened in Boston providing a home away from home for cancer patients and their families who must travel to receive treatment. AstraZeneca employees and family members helped set up bedrooms and decorated bathrooms prior to the opening. A committee of scientists and artists from the Boston research and development site provided art for the new building

and a holiday raffle raised money, which is being used to place a journal in each of the 40 suites. Plans are underway for ongoing employee volunteer projects at the Hope Lodge.



• Making Strides Against Breast Cancer


In 2008, 300 employees, friends and family from AstraZeneca made the walk along the Charles River. AstraZeneca's Vice President for Cancer Research, Jeff Hanke, spoke from the Hatch Shell stage to the 40,000 walkers.

Putting an Emphasis on Science Education

AstraZeneca R&D Boston also takes a leadership role in a number of programs that expand science and technology in the schools. In 2008, David Reif, Associate Director, Cancer Research was appointed Chairman of the Board of Massachusetts BioTeach, a program that supports hands-on biotech education in 162 of the state's public high schools. The goal is to develop active programs in all high schools. In addition, cancer and infection scientists annually judge the Massachusetts Science Fair. In 2008, AstraZeneca also participated in a collaborative study among industry, academia, and state government to recommend strategies to strengthen the talent pipeline for biotech and pharmaceutical employers.

In 2009, we plan to continue to partner with patient-focused organizations dedicated to disease awareness and prevention, research and education, and access to healthcare.

VOLUNTEER SPOTLIGHT



Hongxing Wang

Every Thursday, you will find Hongxing Wang in the emergency room at Wilmington Hospital in Delaware, talking with patients and their families who may be feeling anxious as they wait to see healthcare practitioners. He has learned that just by making himself available to talk to patients, it can really make a difference in their healthcare experience.

Hongxing also works with patients to identify their needs. He often helps comfort patients by offering pillows and blankets to them and bringing food and drinks to their family members.

Hongxing feels very much at home in the hospital environment. He graduated from medical school in China before joining AstraZeneca in 1998, where he has dedicated his career to medical discovery. He views his work at the hospital as just another way to meet the needs of patients. In 2008, Hongxing volunteered 144 hours of his time in the ER.

“Getting to know the patients and their relatives, and being able to provide help or comfort to them means a great deal to me,” explained Hongxing. “The joy I feel is different from what I experience from anything else.”

Hongxing learned about the opportunity to serve at Wilmington Hospital through the AstraZeneca Healthcare Heroes program, an initiative that matches employees with volunteer opportunities at healthcare facilities in and around Wilmington.



Sandy Merritt

AstraZeneca employee Sandy Merritt is a leading founder of Healthcare Heroes, which launched in November 2006. The program matches AstraZeneca employees with volunteering opportunities at healthcare facilities in and around Wilmington, Delaware. This highly successful initiative has provided AstraZeneca volunteers with many different ways to get involved—and to make a difference—in the lives of local patients.

According to Sandy, offering varied levels of involvement and flexible time commitments are among the keys to the program’s success. “Employees who want hands-on involvement can interact with patients directly,” Sandy explains. “Those who aren’t as comfortable in such a role can work behind the scenes at a facility, making phone calls or performing other administrative functions. Volunteers can also participate in collection efforts, helping to gather and deliver items to facilities. Or they can simply make monetary donations. Each level of participation is equally important. We have something to everyone, from one hour a year to a weekly activity.”

AstraZeneca’s partners in the Healthcare Heroes initiative include the A. I. duPont Hospital for Children, St. Francis Hospital, and the Christiana Care Health System, among other organizations.

More than 100 AstraZeneca employees volunteered at Delaware healthcare facilities in 2008.

VOLUNTEER SPOTLIGHT



Anne Cobuzzi

AstraZeneca employee Anne Cobuzzi volunteers with the American Heart Association (AHA) through the local Southeastern Pennsylvania chapter and as a member of the affiliate board of directors that covers the states of Delaware, Pennsylvania, Kentucky, Ohio and West Virginia. Anne's commitment and personal leadership is important to her work for this organization, whose mission is to prevent heart disease, the leading cause of death in the western world. Anne has been a volunteer leader for AHA since 2003 and over the past five years has personally raised over \$500,000 for cardiovascular research.

Anne has been recognized nationally by the AHA organization. She won the Outstanding Leadership Awards from AHA in 2006 and 2007, and in 2008 was awarded the Distinguished Achievement Award from the organization's Affiliate Board of Directors.

Anne serves as Vice-Chair of the Philadelphia Heart Ball, which raises over \$1 million annually for cardiovascular research, as well as organizing AstraZeneca START walk teams for local events. She also supports youth programs such as Jump Rope for Heart in elementary schools.

In addition to her own volunteer work, Anne challenges other AstraZeneca employees to become volunteers in their communities.

Looking ahead: Our goals for 2009 and beyond...

- Maintain leadership and deliver strategic alliances and support of community health stakeholder organizations to advocate for improved patient health
- Continue to help make our medicines available to those in need
- Accelerate the opening of five new American Cancer Society Patient Navigator sites in the next five years
- Open the Philadelphia AstraZeneca Hope Lodge to continue to provide patients and their families free temporary housing when undergoing treatment at cancer center located a distance from their homes

Responsible Business, Healthier Environment

Being a company that's committed to helping people live longer, healthier lives inspires us to be a good steward of the environment today and tomorrow. Through energy conservation, waste reduction and other measures, we are responsibly managing our environmental footprint.

As a global company, we have a framework for safety and environmental programs that encompasses our locations worldwide, governed by local best practices and regulations. In the US, our safety and environmental leadership team works closely with line management to develop strategies, track performance and ensure not only compliance, but also a culture of employee engagement reflected in individual safety and environmental goals and objectives.

In 2008, we made great progress with our environmental efforts in the US. Two of our Delaware buildings achieved LEED® certification, with one becoming the first building in Delaware to be certified at a gold level. We also continued to reduce our hazardous waste and implemented new plans to recycle and reuse waste. Our employees also took responsibility on themselves to minimize their impact on the environment with employee-led programs resulting in the recycling of 2,000 pounds of paper.

Environmental Stewardship in Our Operations

Just as AstraZeneca is committed to helping people lead healthier lives, we are also committed to responsibly managing our environmental footprint. The ongoing US environmental strategy includes ensuring our compliance with federal, state and local regulations as well as effecting positive change in such areas as energy use and carbon dioxide (CO₂) reduction, recycling programs for reducing waste that goes to landfills, improving biodiversity, researching the impact of pharmaceuticals on the environment and collaborating with local environmental organizations. Engaging our employees in all these programs is essential for the protection of our environment.

2008 Environmental Highlights:

- Earned Energy Star certification on two buildings at AstraZeneca Delaware sites and LEED® gold certification on our Biomedical Research Laboratory and Service Provider Center
- Reduced 2008 hazardous waste by 21 percent compared with 2007 levels
- 67 percent of total waste was reused, recycled or incinerated with energy recovery

Conserving Energy, Addressing Climate Change

We have established ambitious worldwide targets for the reduction of greenhouse gas emissions. AstraZeneca US is committed to doing its part to help the company meet these targets by identifying ways to conserve energy and implement more energy-efficient processes.

Globally, we aim to reduce the absolute greenhouse gas emissions associated with our operations by 12 percent by 2010, compared with 2005 levels. To accomplish this in the US, we are implementing energy efficiency initiatives across all sites, reducing the carbon footprint of our electrical supply and investing in renewable energy credits in the form of wind energy.



Two of our buildings in Wilmington received the Energy Star Label for efficiently managing energy. Our employees participated in the Energy Star Change a Light program by exchanging inefficient incandescent light bulbs for energy-efficient compact fluorescent lights, saving 1.3 million pounds of greenhouse gases over the life of the bulbs.



Responsible Business, Healthier Environment

Also in 2008, two of our buildings received LEED® (Leadership in Energy and Environmental Design) gold certification by the US Green Building Council (USGBC). The renovated 95,000-square-foot Biomedical Research Laboratory is the first laboratory in Delaware to achieve LEED certification and only the second building in Delaware to be certified at the gold level. During the renovation process, we recycled 6.8 million pounds of construction debris. Energy-efficient motion detectors were installed to control lighting and heating/cooling, and recycled materials were incorporated into walls, flooring and countertops. Our new Service Provider Center incorporates energy-efficient features including a geothermal heating and cooling system, a trombe wall and solar panels. In the US, all new construction and major renovations will be designed to achieve LEED certification.

Other sites also made progress in 2008 by installing motion detectors and energy-saving light bulbs, reducing lighting levels in low-use areas and significantly reducing lighting during non-business hours. The Newark site completed installation of a heat recovery system that will produce an annual savings equivalent to more than 500,000 pounds of CO₂ emissions

Creating a More Efficient Vehicle Fleet

In 2008, we expanded our hybrid fleet to 194 vehicles out of a sales fleet of around 6,500 vehicles in the US.

This hybrid program, combined with improvements in vehicle maintenance, elimination of minivans and enhanced driver training to maximize fuel efficiency, will help us reduce fleet-related CO₂ emissions. Despite our hybrid fleet expansion, we recognize that only having 3% of our US vehicle inventory using hybrid technology is not satisfactory and that we need to do more.

The hybrid fleet averages 34 miles-per-gallon, saving more than 78,604 gallons of fuel and more than 1.5 million pounds of carbon dioxide emissions compared with the 2005 baseline of 20.5 miles per gallon. To further reduce auto emissions associated with employee travel

to and from work, AstraZeneca provides employees who commute to work with a variety of options and services, including carpool networks, telecommuting opportunities and WageWorks® pretax services for mass transit use.

Reducing Waste; Increasing Recycling

In the US, we reduced our 2008 total hazardous waste by 20 percent from 2007 levels, and 2008 total non-hazardous waste decreased by 16 percent over 2007. Of our total waste, 67 percent was reused, recycled or incinerated with energy recovery. This figure includes 65 percent of our hazardous waste and 67 percent of our non-hazardous waste.

We continue to look for opportunities to minimize waste. AstraZeneca globally has set an ambitious global goal of an 11 percent reduction in the total amount of waste we generate worldwide from 2005 levels, indexed to sales (tons/\$m sales) by 2010. To help reach this goal, each of our US sites have waste minimization plans in place that include initiatives to eliminate, reduce or recycle our waste. One example is the installation of copiers with a default duplex setting that uses 20 to 25 percent less paper. At our Waltham site, that savings translated to 55,000 sheets of saved paper.

Our employees are also taking ownership of their environment by incorporating sustainable thinking into their day-to-day routines to help drive waste reduction. For example, an employee at our Wilmington research and development facility challenged his colleagues to reduce waste, so they developed a comprehensive recycling program. They recycle office paper, but also cardboard boxes, bottles, paper shoe covers and Tyvek® uniforms. From May to August of 2008, they recycled 1,200 pounds of uniforms. They even recycle the plastic bags that cloth uniforms are packed in after laundering. Tyvek uniforms are also being recycled at our Newark site.

Other employees have placed battery recycling stations throughout the Wilmington and Newark campuses and held spring and fall cleanups that recycled 2,000 pounds of paper.



Responsible Business, Healthier Environment

Sustaining Biodiversity at Our Sites

In 2008, AstraZeneca completed a biodiversity survey for all sites in Delaware and Massachusetts. Results from this survey will be used to guide our land management and we are making progress toward increasing the biodiversity of our campuses.

The Newark facility was the first AstraZeneca location to join the EPA Greenscapes Alliance Partnership Program earlier this year. The site partnered with the Delaware Department of Agriculture Forest Service to plant 140 native trees and shrubs to provide future habitats. Combined with additional trees planted last year, the site has reclaimed more than 10 acres of green space.

In Waltham, Massachusetts, the laboratory expansion in progress includes a plan to minimize the impact of landscaping on the immediate environment. The site uses no pesticides or herbicides, minimal fertilization (only low-grade nitrogen fertilizer) and native plantings. Minimal irrigation conserves water resulting in less runoff into an adjacent wetland. Mowing is done only to keep walkway areas and electrical housings clear, leaving fields that are inviting to wildlife.

Environmental Stewardship of Our Products

Our commitment to safety, health and the environment (SHE) also includes efforts to better understand and manage the way our products interact with the environment. Globally, we have put programs in place that integrate SHE standards in product development and manufacturing design. Other programs integrate our SHE practices throughout our supply chain to promote vigilance and performance by our partners.

The US participates in industry groups that are studying the scientific and policy issues associated with the environmental impact of our products. We recognize that important policy and scientific questions remain as we continue to work to ensure that our products are devel-

oped, manufactured, used and disposed of in a manner that minimizes their potential impact on the environment. Our goal is to improve in this area and we are beginning with employee awareness of PIE and educating employees on the appropriate disposal of pharmaceuticals in the home. In 2009, AstraZeneca US will be launching employee engagement campaigns to help minimize our employees' impact on the environment both at work and home.

Environmental Stewardship in Our Communities

Our employees are at the heart of our commitment to safety, health and the environment. One significant component of our work in this area involves our voluntary, grass-roots efforts by a staff of dedicated environmental stewards. Through company sponsorships and employee volunteerism, AstraZeneca has partnered with local and state environmental nonprofits to engage the public and help preserve the natural spaces that are important wildlife habitats and places of recreation. These include programs such as Adopt-A-Highway, Beach Grass Planting, River Cleanups, Energy Fairs and Earth Day events. In 2008, we supported the Community Greening Program of the Delaware Center for Horticulture, the Delaware Greenways, "No Child Left Indoors" festival, the Delmarva Ornithological Society Bird-a-thon, and tree plantings by ErthNxt and the Nature Conservancy.



Looking Ahead: Goals for 2009 and Beyond...

Global Safety, Health and Environment (SHE) Objectives and Targets (2006—2010)

Objectives:

- Aim to eliminate all work-related injuries and cases of ill health by providing a safe and healthy work environment and promoting health and well-being.
- Aim for continuous improvement in the sustainability of all our activities by using fewer natural resources and working to eliminate pollution.
- Train, empower and require individuals to take personal responsibility for safety, health and the environment.

Targets:

- Reduce by 50 percent from 2001/2002 levels the combined frequency rate of accidents resulting in fatal or serious injuries and new cases of occupational illness.
- Maintain our total greenhouse gas emissions at 2001/2002 levels.
- Reduce total waste, indexed to sales, by 11 percent from 2005 levels.
- Institute training and behavioral initiatives designed to continuously improve our SHE culture across the organization.



US Corporate Headquarters

AstraZeneca Pharmaceuticals LP

1800 Concord Pike

P.O. Box 15437

Wilmington, DE 19850-5437

